by James R. Berenson, MD; Carol Ann Huff, MD; and Paul G. Richardson, MD
While lenalidomide as maintenance therapy is the strategy for most patients with multiple myeloma, there is ongoing debate about how maintenance th......READ MORE
by James R. Berenson, MD; Carol Ann Huff, MD; and Paul G. Richardson, MD
Individualized treatment for multiple myeloma currently draws on many factors, including patient characteristics, tumor burden, cytogenetic risk, a......READ MORE
The International Myeloma Working Group (IMWG) Updated Criteria for the Diagnosis of Multiple Myeloma allow for the early identification of active ......READ MORE
Methods for evaluating a patient’s disease status have not kept pace with the expanding profile of therapeutic options. Emerging biomarkers promise......READ MORE
For fit patients with multiple myeloma, triplet therapy is often the preferred primary treatment, regardless of whether or not they are eligible fo......READ MORE
Renal impairment is common in patients with multiple myeloma. It stems from a variety of causes, and treatment must be approached carefully. Our fe......READ MORE
